Literature DB >> 6267997

Gynecomastia with ketoconazole.

R DeFelice, D G Johnson, J N Galgiani.   

Abstract

Three of forty men developed bilateral gynecomastia upon ketoconazole treatment. Symptoms abated despite continued therapy. This appears to be a direct drug effect on breast tissue.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6267997      PMCID： PMC181611          DOI： 10.1128/AAC.19.6.1073

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Estrogen metabolism in hyperthyroidism and in cirrhosis of the liver.

Authors:  J Olivo; G G Gordon; F Rafii; A L Southren
Journal:  Steroids       Date:  1975-07       Impact factor: 2.668

2.  Gynecomastia. Its incidence, recognition and host characterization in 447 autopsy cases.

Authors:  M J WILLIAMS
Journal:  Am J Med       Date:  1963-01       Impact factor: 4.965

3.  Gynecomastia during digitalis therapy; report of eight additional cases with liver-function studies.

Authors:  E B LEWINN
Journal:  N Engl J Med       Date:  1953-02-19       Impact factor: 91.245

4.  Case report. Gynecomastia following digitalis administration.

Authors:  C J Wolfe
Journal:  J Fla Med Assoc       Date:  1975-12

5.  Conversion of androgens to estrogens in cirrhosis of the liver.

Authors:  G G Gordon; J Olivo; F Rafil; A L Southren
Journal:  J Clin Endocrinol Metab       Date:  1975-06       Impact factor: 5.958

6.  Ketoconazole: a major innovation for treatment of fungal disease.

Authors:  J R Graybill; D J Drutz; A L Murphy
Journal:  Ann Intern Med       Date:  1980-12       Impact factor: 25.391

7.  Estrogen-like activity of digitalis: its effect on the squamous epithelium of the female genital tract.

Authors:  A Navab; L G Koss; J S LaDue
Journal:  JAMA       Date:  1965-10-04       Impact factor: 56.272

8.  Therapy of disseminated or pulmonary coccidioidomycosis with ketoconazole.

Authors:  C Brass; J N Galgiani; S C Campbell; D A Stevens
Journal:  Rev Infect Dis       Date:  1980 Jul-Aug

9.  Spironolactone and endocrine dysfunction.

Authors: 
Journal:  Ann Intern Med       Date:  1976-11       Impact factor: 25.391
  9 in total
  29 in total

Review 1.  CYP17 inhibitors for prostate cancer therapy.

Authors:  Tadas S Vasaitis; Robert D Bruno; Vincent C O Njar
Journal:  J Steroid Biochem Mol Biol       Date:  2010-11-17       Impact factor: 4.292

Review 2.  Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

Authors:  Irina Veytsman; Lynnette Nieman; Tito Fojo
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

Review 3.  Hormonal aspects of prostatic cancer: a review.

Authors:  J Waxman
Journal:  J R Soc Med       Date:  1985-02       Impact factor: 5.344

4.  Preoperative ketoconazole therapy for adrenocortical carcinoma.

Authors:  L J Sinnaeve; G P Becks
Journal:  CMAJ       Date:  1989-07-15       Impact factor: 8.262

Review 5.  The endocrine effects of ketoconazole.

Authors:  N Sonino
Journal:  J Endocrinol Invest       Date:  1986-08       Impact factor: 4.256

Review 6.  Overview of medically important antifungal azole derivatives.

Authors:  R A Fromtling
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

7.  Ketoconazole blocks bile acid synthesis in hepatocyte monolayer cultures and in vivo in rat by inhibiting cholesterol 7 alpha-hydroxylase.

Authors:  H M Princen; C M Huijsmans; F Kuipers; R J Vonk; H J Kempen
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

8.  Cytotoxicity of ketoconazole in malignant cell lines.

Authors:  C F Rochlitz; L E Damon; M B Russi; A Geddes; E C Cadman
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 9.  Antifungal agents used in systemic mycoses. Activity and therapeutic use.

Authors:  J R Graybill; P C Craven
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546

Review 10.  Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.

Authors:  Hui Zhu; Jorge A Garcia
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.